Enhanced proliferation and differentiation effects of a CGRP- and Sr-enriched calcium phosphate cement on bone mesenchymal stem cells
Abstract
Introduction
Because of its good osteoconductivity, strontium (Sr) ranelate has been extensively used as a bone substitute for the treatment of bone disorders. To facilitate treatment, Sr is also incorporated into calcium phosphate cement (Sr-CPC); however, the Sr from Sr-CPC is not sufficient to induce a significant increase of bone mass in an ovariectomized rat model. To improve the efficiency of Sr-CPC, we developed a calcitonin gene–related peptide (CGRP)- and Sr-enriched CPC (CGRP-Sr-CPC).
Methods
We used X-ray diffraction and Fourier transform infrared spectroscopy to measure properties of CGRP-Sr-CPC. We also employed a cell proliferation assay, alkaline phosphatase (ALP) assay and real-time PCR to assess the effects of CPC implants on proliferation and differentiation of bone mesenchymal stem cells (BMSCs) from an ovariectomized rat model.
Results
CGRP did not change the composition, pore sizes and compressive strength of the cement body as compared with Sr-CPC. Meanwhile, CGRP-Sr-CPC did not show cell cytotoxicity to BMSCs. Further, CGRP and Sr released from CGRP-Sr-CPC significantly enhanced the cell proliferation of BMSCs and increased the activity of ALP during differentiation of BMSCs, compared with CGRP- or Sr-CPC. Moreover, CGRP-Sr-CPC significantly up-regulated the expression levels of osteogenic differentiation-related genes including Alp, Bmp2, Osteonectin and Runx2 during differentiation.
Conclusions
These findings demonstrate the optimized effects of CGRP- and Sr-enriched CPC in promoting proliferation and osteogenic differentiation of BMSCs, suggesting the potential ability of this novel cement to assist the formation of new bone during osteoporosis-induced bone disorders.
J Appl Biomater Funct Mater 2016; 14(4): e431 - e440
Article Type: ORIGINAL RESEARCH ARTICLE
DOI:10.5301/jabfm.5000295
Authors
Wei Liang, Li Li, Xu Cui, Zhongfei Tang, Xiaomou Wei, Haobo Pan, Bing Li
Article History
• Accepted on 11/04/2016
• Available online on 08/08/2016
• Published online on 02/11/2016
Disclosures
Financial support: This study is supported by National Natural Science Foundation of China (No:81260273).
Conflict of interest: The authors declare that they have no conflicts of interest.
Osteoporosis is a potential bone disorder, which usually causes an increase of risk of bone fracture and bone defect incidence (1, 2). In osteoporosis, there is a reduction of the differentiation and a decrease of the potential of osteoblasts, and an increase of the differentiation of adipocytes (3). These alterations result in a loss of bone mass and bone mineral content in osteoporotic patients (4). Bone mass is regulated by new bone formation and replacement of damaged bone, processes which are referred to as bone remodeling (5). Bone metabolism, resorption and performance are modulated by the nervous system (6). The nervous fibers from the nervous system secret neurotransmitters including calcitonin gene–related peptide (CGRP), neuropeptide and substance P to regulate the performance of bone tissues and osteoblast activities (7, 8). CGRP plays a role in promoting bone healing and remodeling in fracture patients with osteoporosis (9). Recent studies have demonstrated that exogenous CGRP increased bone mesenchymal stem cell (BMSC) proliferation and osteogenic potential in physiological conditions (9, 10). A recent study by our group also suggested that CGRP induces proliferation and osteogenic differentiation of BMSCs in the pathological environment (11).
To achieve the goal of bone remodeling and osseointegration, implant materials are frequently used (5, 12-13-14-15). Calcium phosphate cement (CPC) is one of the materials widely used as a bone substitute, because of its good biocompatibility (16-17-18-19). In addition, the potential utilization of CPC as a carrier for various osteoinductive factors has been extensively studied. For example, factors modulating bone formation (20-21-22-23-24) are implanted into materials to enhance osseointegration and osteoconductivity. In addition, strontium (Sr), an important element of human body, has become such a factor because of its effects on inhibition of bone resorption and stimulation of bone formation (25, 26). Sr implanted in CPC increases the expression levels of osteoblast-related genes and promotes the activity of alkaline phosphatase (ALP) in an osteoblast-like cell line and BMSCs (27-28-29). However, one study showed that systemic release of Sr from Sr-CPC implants does not lead to high enough serum Sr levels to generate an increase of bone mass in ovariectomized (OVX) rats (30), which suggests its effect on the treatment of osteoporosis has to be improved. To enhance the effects and overcome the limitations of Sr-CPC, we proposed to combine CGRP with Sr in CPC (CGRP-Sr-CPC) implants. To achieve that, we developed a CGRP- and Sr-enriched CPC. This CPC has similar composition, pore sizes and compressive strength of the cement body to Sr-incorporated CPC. In addition, CGRP-Sr-CPC showed excellent biocompatibility with BMSCs derived from OVX rats and did not show cell cytotoxicity in these cells. CGRP-Sr-CPC significantly enhanced proliferation and osteogenic differentiation of BMSCs. These findings demonstrated the enhanced effects of CGRP and Sr in regulation of proliferation and differentiation of BMSCs isolated from osteoporotic bone.
Materials and methods
Preparation of materials
To make an implant of CPC, dicalcium phosphate anhydrous (DCPA; Alfa Aesar) together with tetracalcium phosphate (TTCP; Wako, Japan) were mixed as previously described (31, 32). For the Sr-CPC group, strontium hydrogen phosphate (DSPA; Sigma) was used to partially replace DCPA to make a total molar ratio for Sr/(Sr.Ca) of 10%. The liquid phase consisted of a mixture of 12 wt% polyvinylpyrrolidone K-30 (PVP; Wako, Japan) and 20 wt% citric acid (Wako, Japan). Then, the cement paste was made in a mixture with 2 different phases: the liquid and solid phases. For the CGRP-CPC and CGRP-Sr-CPC groups, the CPC or CPC-Sr was immersed with 0.5% CGRP buffer for 24 hours to make the materials absorb the CGRP completely. For the CGRP/Sr-CPC group (addition of free CGRP to the Sr-CPC group), 200 pg/mL of CGRP was added together with the Sr-CPC group to BMSC cultures daily.
Measurement of compressive strength
The cement samples, which had a diameter of 6 mm and a height of 12 mm, were incubated with simulated body fluid (SBF) at a temperature of 37°C (33), for 1, 7, 14 or 28 days. Then the compressive strength of CPC, Sr-CPC, CGRP-CPC or CGRP-Sr-CPC was measured by a MTS 858 Bionix testing machine (MTS Systems, Minneapolis, MN, USA). In particular, continuous loads were applied to the samples, which were placed between the plates of the machine with the axis along the center. The compressive strength was measured when the sample broke down. In detail, a 1-kN load cell at a rate of 0.1 mm/min was continuously exerted on the samples until breakdown occurred. Five samples were tested in each group at 1 time point.
Measurement of composition and observations of morphology
The samples were incubated in SBF at 37°C for 1, 14 and 28 days, followed by immersion in liquid nitrogen for 30 minutes to stop the reaction, as described before (31). Next, the samples were dried out with ModulyoD-230 (Thermo Electron Corp., Marietta, OH, USA) and ground into small powders. Then, X-ray diffraction (XRD; Rigaku, Tokyo, Japan) and Fourier transform infrared (FTIR) spectroscopy (Perkin-Elmer, Waltham, MA, USA) were used to measure the constitution and structure of the samples. Meanwhile, electron microscopy (LEO 1530 VP; LEO 1530 FESEM, Oxford, UK) was used to scan the morphology of the surface of the samples. The images were collected with a secondary electron detector under high vacuum (30 Pa) at an acceleration of 15 kV.
Measurement of pore size distribution
The pore size distribution of cements was determined using micro-computed tomography (micro-CT; Skyscan1076; Skyscan, Kontich, Belgium). The micro-CT was tuned at 70 kV and 140 μA, with a resolution of 9 μm. Micro-CT shadow projection images were converted into a 3-dimensional (3D) reconstruction of cross-sectional images in bitmap files using volumetric reconstruction software (Nrecon software; Skyscan, Belgium). The pore size was calculated from these 3D reconstructions using CTAn software (SkyScan, Kontich, Belgium).
Measurement of degradation of CPC samples in vitro
The CPC (CPC or CGRP-Sr-CPC) samples were immersed in SBF (mass to volume ratio = 0.2 g/L) for 28 days. Each day, the samples were taken out, dried and weighed. Then, the samples were immersed again in fresh SBF. The percentage of residual mass of each sample was calculated as (Wt × 100)/Wo, where Wt was the weight of the sample after immersion in SBF, and Wo was the initial weight of the sample before immersion in SBF.
Measurement of CGRP and Sr concentrations
CGRP-Sr-CPC was incubated in SBF (mass/volume = 1.25 cm2/mL) for 1 to 28 days. The cement samples immersed in SBF were gently shaken at 37°C. A portion of the immersed SBF buffer was removed each day for ELISA analysis to measure CGRP concentration as described in a previous report (11). The amount of Sr was measured using inductively coupled plasma–mass spectrometry (ICP-MS) assay according to the method previously published (34). The experiments were repeated 3 times.
Isolation and culture of BMSCs
BMSCs were generated from femoral and tibial bone marrow of OVX female mice as reported previously (11). BMSCs were plated with 6 × 105 cells/60-mm dish and cultured in Dulbecco’s modified Eagle’s medium (DMEM) medium with 10% fetal bovine serum (FBS) in an incubator at 37°C with 5% CO2. Culture medium was replaced every 3 days, and the cells were passaged with 0.25% trypsin (#25200-072; Gibco) when they reached 80% confluence.
Cytotoxicity assay
We performed an indirect cytotoxicity assay to measure the cytotoxicity of the cement samples. To do that, extracts from cell culture medium with immersed cement samples were prepared. Phenol solution (0.02%) in phosphate-buffered saline (PBS) diluted with culture medium was used as a positive control extract. The negative control was collected by incubating an innocuous pure titanium sample in culture medium for 24 hours at 37°C. BMSCs were diluted at 1 × 104 cells/mL in culture medium, and then 100 μL of BMSCs was added to each well in a 96-well plate, followed by incubation of BMSCs for 24 hours at 37°C. Then the cell medium was replaced by the extracts from cell culture medium with immersed cement samples as mentioned above. Next, the plates were incubated for 4 hours. After that, cell viability was measured using a WST-1 assay kit according to protocol (Cat. no. 05015944001; Roche). Triplicated experiments were performed.
Cell morphology
BMSCs with a density of 2 × 104 cells/mL were added to each well in a 24-well plate. In each well, there was a cement disk with a diameter of 12 mm and a thickness of 2 mm. After culture for 1 or 14 days, the sample cell constructs were carefully washed twice with PBS, followed by fixation with 4% formalin. Next, the sample was dehydrated with a gradient of ethanol: 50%, 70%, 90%, 95% and 100%. The samples were then dried using liquid CO2 and coated with a layer of gold of 20-nm thickness. The morphology of the cells, which were in contact with the samples was observed with a scanning electron microscope.
Cell proliferation assay
BMSCs at passage 3 (P3) were dissociated and cocultured with the cement samples 6 mm in diameter and 2 mm in height in a 96-well plate at 2.5 × 104 cells per well. After culture for 1, 3, 5 or 7 days, a MTT assay was performed according to protocol using a commercial kit (#V13154; Life Technologies). Three experiments were performed at each time point for each cement sample.
Measurement of ALP activity
Cells were plated to 24-well plate at 5 × 104 cells per well and co-cultured with the cement samples with a diameter of 12 mm and a height of 2 mm. After culture for 1, 3, 7 or 14 days, ALP activity was performed using an ALP assay kit according to the manufacturer’s protocol (#ab83369; Abcam). Triplicate experiments were performed.
Real-time PCR
BMSCs cultured on the cement samples for 1, 3, 7 or 14 days were subjected to RNA extraction using TRIzol reagent (#15596-066; Invitrogen). Quantitative PCR was performed in accordance with a previous report (35). PCR primers are listed in Table I.
Primers used for quantitative PCR
Gene
Primer sequences: 5’~3’
Alkaline phosphatase (Alp)
F: CGTTGACTGTGGTTACTGCTGA
R: TTGTAACCAGGCCCGTTG
Bmp2
F: CGTGCTCAGCTTCCATCAC
R: CCTGCATTTGTTCCCGAAA
Runx2
F: TTTGCAGTGGGACCGACA
R: AGCCATGGTGCCCGTTAG
Osteonectin
F: CTCCCATTGGCGAGTTTG
R: TGTAGTCCAGGTGGAGCTTGTG
Gapdh
F: CACAGTCAAGGCTGAGAATG
R: GGTGGTGAAGACGCCAGTA
Statistical analysis
All experiments were repeated at least 3 times independently. Graphs were generated with SPSS statistical software, version 19.0 (SPSS, Chicago, IL, USA). Two-way analysis of variance (ANOVA) followed by Tukey multiple comparisons was performed to determine the significance of the different treatments of implants at different time points. Data are expressed as means ± SD. A value of p less than 0.05 was considered significant.
Results
Composition of the cement samples
To analyze the composition of the CPC, Sr-CPC, CGRP-CPC and CGRP-Sr-CPC, the XRD and FTIR techniques were used. With immersion in SBF for 1 day, the cement samples were analyzed with XRD. The data showed that there were intensive peaks for TTCP and DCPA (CPC and CGRP-CPC) or DSPA (Sr-CPC and CGRP-Sr-CPC), which are characteristic of the starting materials (Fig. 1A, B). We noted that there was an absence of any peaks of hydroxyapatite (HA), suggesting that the composition of the cements was in the original solid phase at this stage. Then, FTIR spectroscopy was performed,
and it showed that the symmetric COO band was present at around 1,430 cm-1 and the antisymmetric COO band was present at 1,600 cm-1 in all CPC samples (Fig. 1C), demonstrating an occurrence of a chelated reaction in the body of the cements. The results also showed that there were no obvious differences between CPC and CGRP-CPC or between Sr-CPC and CGRP-Sr-CPC samples, suggesting that CGRP did not interfere with the initial chemical reactions in the cement body.
Composition of cement samples after immersion in simulated body fluid (SBF). The cement samples including calcium phosphate cement (CPC), strontium (Sr)-enriched CPC (Sr-CPC), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC) and CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) were analyzed with X-ray diffraction (XRD) (A) or Fourier transform infrared (FTIR) spectroscopy (C) after 1 day of immersion in SBF. The rectangle in (A) is shown amplified in (B). After 28 days of immersion in SBF, the composition of cement samples was analyzed with XRD (D) and FTIR (E). DCPA = dicalcium phosphate anhydrous; DSPA = strontium hydrogen phosphate; HA = hydroxyapatite; TTCP = tetracalcium phosphate.
Then we examined the composition of cement samples that were immersed in SBF for 28 days. We found that the intensity of the original peaks of DSPA and TTCP remained but decreased gradually, and the intensive peaks of HA were observed, suggesting that most of the initial phases were converted into apatite (Fig. 1D). This result was consistent with our observations that there were typical characteristic peaks of PO4 at around 1,033 cm-1 and around 560-600 cm-1, respectively (Fig. 1E). We also noted a deviation of the FTIR peaks of around 850 cm-1 and 1,400 cm-1 on the right side (Fig. 1E), which may have been due to the incorporation of carbonate. In addition, we assayed the degradation of CPC and CGRP-Sr-CPC in SBF buffer. Overall, both cements slightly degraded after immersion in SBF in vitro, and CGRP-Sr-CPC (degraded by ~12% on day 28) showed a rapid degradation as compared with CPC (degraded by ~5.9% on day 28) (Suppl Fig. 1 available online as supplementary material at www.jab-fm.com).
Morphology of the cement samples
To confirm the results of XRD and FTIR, we used scanning electron microscopy to scan the fractured surfaces of the samples. The data showed that the fractured surfaces were composed of entangled structures and irregular patterns after 1-day immersion of cements in SBF (Fig. 2A-B-C-D). The fractured surface that was exposed to the SBF solution was covered by a precipitation of apatite after 28 days of immersion of cements in SBF (Fig. 2E-F-G-H). These observations were consistent with the observations with XRD and FTIR that the precipitation of apatite was present after cements had been immersed in SBF for 28 days. In addition, we did not observe any differences between Sr-CPC and CGRP-Sr-CPC after immersion in SBF for 1 or 28 days (Fig. 2B, D, F and H).
Scanning electron microscopy images showing morphology of the cement samples after immersion in simulated body fluid (SBF). The fractured surfaces of the calcium phosphate cement (CPC) (A, E), strontium (Sr)-enriched CPC (Sr-CPC) (B, F), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC) (C, G) and CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) (D, H) after immersion in SBF at 37°C for 1 day (A-D) and 28 days (E-H). Scale bar = 2 μm, applies to all images.
Pore size distribution and compressive strength of samples
To further characterize the cement samples, the pore size and compressive strength of CPC, Sr-CPC, CGRP-CPC and CGRP-Sr-CPC were examined. These cements have similar pore size distributions and mass median pore sizes in a range from 45 to 64 μm (Fig. 3A-B-C-D). The results of compressive strength tests showed there was no significant difference detected in compressive strength for cement samples with the enrichment of Sr or CGRP after immersion in SBF for a day. All cement samples had a mean value of compressive strength of around 15 to 20 MPa (Fig. 3E). The compressive strength increased gradually with immersion in SBF for longer time periods (Fig. 3E). In addition, no significant difference was observed in compressive strength among cement samples with or without Sr or CGRP incorporation (Fig. 3E).
Pore size and compressive strength of the cement samples. The distribution of pore sizes and typical images of calcium phosphate cement (CPC) (A), strontium (Sr)-enriched CPC (Sr-CPC) (B), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC) (C) and CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) (D) are shown. The compressive strength of these cement samples were measured after immersion in simulated body fluid (SBF) for 1, 7, 14 and 28 days as indicated in (E). Concentration of CGRP after CGRP-Sr-CPC had been immersed in SBF for 1 to 28 days, as indicated, was measured with ELISA (F).
Next, we examined the release of CGRP after CGRP-Sr-CPC was immersed in SBF continuously for 28 days. Initially, CGRP had a concentration of 225.9 pg/mL (34.02% released) after CGRP-Sr-CPC had been immersed in SBF for 1 day (Fig. 3F). Then, the release of CGRP gradually increased after CGRP-Sr-CPC had been immersed in SBF for 4 days (97.49% released) and 7 days (99% released) (Fig. 3F). Thereafter, the concentration of CGRP was maintained at a high level of around 620 pg/mL. The release of Sr gradually increased from about 32 mg/L on day 1 to 54 mg/L on day 28 after being immersed in SBF (Suppl Fig. 2 available online as supplementary material at www.jab-fm.com). These results suggest that CGRP and Sr are gradually released, accompanied by degradation of CGRP-Sr-CPC (Suppl Fig. 1).
CGRP and Sr released from CGRP-Sr-CPC enhance proliferation of BMSCs
To investigate the effects of cements on BMSCs derived from pathological conditions, BMSCs isolated from osteoporotic rat tissues were cocultured with cement samples. The BMSCs were grown on a flat surface and spread on the surfaces of the samples with coculture for 1 day (Fig. 4A-B-C-D). After coculture for 14 days, the cement surface was almost covered with a confluence of cells in all groups, suggesting a good compatibility between cells and cement samples (Fig.4E-F-G-H). Consistent with the morphological observations, the cytotoxicity tests showed that all extracts from cocultures of BMSCs with the cement samples had a relative cell viability of 100%, compared with the negative control group, indicating there was no cytotoxicity for these cement samples (Fig. 5A).
Scanning electron microscopy images showing morphology of bone mesenchymal stem cells (BMSCs) on the surfaces of cement samples. BMSCs were cocultured with calcium phosphate cement (CPC) (A, E), strontium (Sr)-enriched CPC (Sr-CPC) (B, F), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC) (C, G) or CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) (D, H) for 1 and 14 days. The cells become flattened after coculture for 1 day (A-D) and covered almost all of the cement surface after coculture for 14 days (E-H). Scale bar = 2 μm, applies to all images.
Cytotoxicity and proliferation-inductive effects of the cement samples on bone mesenchymal stem cells (BMSCs). The cement samples as indicated had no cytotoxicity compared with negative control (NC), while the positive control (PC) group showed a strong ability to suppress cell growth (A). The proliferation-inductive effects of the cement sample BMSCs were measured with MTT assay after BMSCs were cocultured with different cement samples for 1, 3, 5 and 7 days (B). *p*0.05, **p*0.01; strontium (Sr)-enriched calcium phosphate cement (Sr-CPC), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC), CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) or free CGRP added to Sr-enriched CPC (CGRP/Sr-CPC) group vs. the CPC group.
Next we measured the effects of cement samples on proliferation of BMSCs. After culture for 1 day, there was no significant difference among all groups. After culture for 3 days, there was no significant difference between the CPC and Sr-CPC groups or between the CGRP-CPC and CGRP-Sr-CPC groups, but a significantly higher proliferation rate was detected in the CGRP-CPC and CGRP-Sr-CPC groups compared with the CPC and Sr-CPC groups (Fig. 5B). After culture for 5 and 7 days, the Sr-CPC and CGRP-CPC groups a significantly higher proliferation rates compared with the CPC group (Fig. 5B), suggesting that both Sr and CGRP promote proliferation of BMSCs. Notably, the CGRP-Sr-CPC group enriched by both CGRP and Sr showed enhanced effects on proliferation of BMSCs as compared with CPCs with CGRP or Sr alone (Fig. 5B), indicating that CGRP together with Sr strengthened and optimized the efficiency of the promotion of proliferation of BMSCs. In addition, adding free CGRP to Sr-CPC (CGRP/Sr-CPC) had a similar effect on proliferation of BMSCs compared with CGRP-Sr-CPC (Fig. 5B), which confirmed the role of CGRP and Sr on BMSCs.
CGRP-Sr-CPC has enhanced effects on induction of ALP activity
To further evaluate the effects of cements on regulation of differentiation, we measured the ALP activity. After culture for 1 day, the ALP activity was relatively low, and there were no significant differences among BMSC cultures with different cement groups (Fig. 6). After culture for 3 days, there were no significant differences among the Sr-CPC, CGRP-CPC, CGRP-Sr-CPC and CGRP/Sr-CPC groups, but there was a significantly higher ALP activity for these groups compared with the CPC group (Fig. 6). On days 7 and 14, the Sr-CPC and CGRP-CPC groups showed a significantly higher level of ALP activity compared with the CPC group (Fig. 6), suggesting that both Sr and CGRP induce ALP activity during coculture with BMSCs. The CGRP-Sr-CPC and CGRP/Sr-CPC groups showed enhanced effects on induction of ALP activity compared with the CGRP-CPC and Sr-CPC groups (Fig. 6). Altogether, the data suggest that either CGRP or Sr could increase ALP activity during differentiation of BMSCs, while the combination of CGRP and Sr has an enhanced effect on ALP activity.
(A) The efficiency of the cement samples in inducing alkaline phosphatase (ALP) activity during bone mesenchymal stem cell (BMSC) differentiation. ALP activity was assayed after BMSCs were cocultured with cement samples for 1, 3, 5 and 7 days (B). *p*0.05, **p*0.01; strontium (Sr)-enriched calcium phosphate cement (Sr-CPC), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC), CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) or free CGRP added to Sr-enriched CPC (CGRP/Sr-CPC) group vs. the CPC group.
CGRP-Sr-CPC increases expression of osteogenic differentiation–related genes
To validate the inductive role of CPC samples during osteogenic differentiation, genes associated with osteoblast differentiation were examined. Cells cocultured with CPC, Sr-CPC, CGRP-CPC or CGRP-Sr-CPC for 1, 7 and 14 days were collected to generate mRNA. The real-time PCR results showed that Sr or CGRP alone could significantly increase expression levels of genes involved in osteogenic differentiation, including Alp, Bmp2, Osteonectin and Runx2 during differentiation for 7 and 14 days (Fig. 7). With the combination of CGRP and Sr, the CGRP-Sr-CPC group showed significantly increased expression of these 4 genes compared with the CGRP-CPC and Sr-CPC groups (Fig. 7). Therefore, CPC with enriched CGRP and Sr has enhanced inductive effects to promote osteogenic differentiation–related gene expression.
The role of the cement samples in regulation of expression levels of osteogenic differentiation–related genes. Bone mesenchymal stem cells (BMSCs) cocultured with different cement samples for 1, 7 or 14 days were harvested for gene expression analysis. Osteogenic differentiation–related genes including Alp (A), Bmp2 (B), Osteonectin (C) and Runx2 (D) were examined. *p*0.05, **p*0.01; strontium (Sr)-enriched calcium phosphate cement (Sr-CPC), calcitonin gene–related peptide (CGRP)-enriched CPC (CGRP-CPC), CGRP- and Sr-enriched CPC (CGRP-Sr-CPC) or free CGRP added to Sr-enriched CPC (CGRP/Sr-CPC) group vs. the CPC group.
Discussion
CPC is one of the widely used bone substitutes for therapy of osteoporotic bone fractures (16-17-18). To improve the effects of CPC, inductive factors that can modulate bone formation, including bone morphogenetic protein 2 (BMP2), insulin-like growth factor (IGF) and Sr, are usually incorporated into the CPC materials (20-21-22-23-24-25-26). Because the effects of the drug strontium ranelate in improving bone-building osteoblasts, assisting bone growth and increasing bone density and bone mass have been demonstrated (36-37-38), Sr is implanted into CPC for the purpose of improvement of osseointegration and osteoconductivity in osteoporotic bones. Studies have shown that Sr-enriched CPC increases the expression levels of osteoblast-related genes and promotes the activity of ALP in osteoblastic-like cell lines and BMSCs derived from physiological conditions (27-28-29-30-29). However, systemic release of Sr from Sr-CPC implants did not generate sufficient Sr to induce significant improvements in bone mass in OVX rats (30). Compared with CPC in this present study, we confirmed that Sr-CPC exerts certain effects on promoting proliferation, inducing ALP activity and osteogenic differentiation–related gene expression in cultured BMSCs isolated from osteoporotic rats.
Considering the limited release of Sr from Sr-CPC in vivo, we sought to find an additional factor that might play a critical role in modulating BMSCs and osteoblast differentiation, to further improve the efficiency of Sr-CPC. CGRP is an ideal candidate for this purpose. CGRP is a peptide synthesized by sensory neurons in the dorsal root ganglion (39). CGRP participates in the regulation of growth, repair and performance of bone by working on BMSCs (40-41-42). Our recent study discovered positive effects of CGRP in stimulation of cell growth and induction of osteogenic differentiation in BMSCs derived from osteoporosis (11). Based on the promising effects of CGRP on BMSCs, we created CGRP-CPC. This cement has similar pore size distribution, compressive strength, biocompatibility and low cytotoxicity compared with CPC or Sr-CPC (Figs. 2-3-4-5). CGRP-CPC promoted BMSC proliferation, induced ALP activity and increased expression of Alp, Bmp2, Osteonectin and Runx2, but did not show obvious enhanced proliferation and differentiation effects compared with Sr-CPC. Then we implanted a combination of Sr and CGRP in CPC. This new cement showed similar pore size distribution, compressive strength, biocompatibility and low cytotoxicity compared with CPC, Sr-CPC or CGRP-CPC. Remarkably, CGRP-Sr-CPC had enhanced efficiency in proliferation of BMSCs, induction of ALP activity and increase of expression levels of Alp, Bmp2, Osteonectin and Runx2, compared with CPC, Sr-CPC or CGRP-CPC (Figs. 5-6-7), demonstrating that Sr and CGRP may act together or alone to strengthen the efficiency in this combined CGRP-Sr-CPC. We noticed that the enhanced effects of Sr and CGRP are most obvious after treatment of BMSCs for 7 days. This may be relevant to the release kinetics of CGRP and Sr, and the proliferation/differentiation stage of BMSCs. At an early time point – for example, on day 1 – the release of CGRP (225.9 pg/mL) and Sr (32 mg/L) as measured in SBF was not sufficient to induce a robust proliferation, osteogenic differentiation or gene expression. On day 7, CGRP released from CGRP-Sr-CPC reached a concentration of about 620 pg/mL (4.4 × 10-11 mol/L, i.e., approximately 99% released), which is close to the physiological concentration of CGRP (43-44-45). The effects of CGRP on promoting proliferation and osteogenic differentiation of BMSCs at this concentration have been demonstrated (11), which is consistent with our results that a combination of CGRP and Sr at this time point exert strong effects on promoting proliferation and inducing osteogenic differentiation. This suggests that CGRP-Sr-CPC may release sufficient CGRP for clinical treatment. Sr was continuously released from CGRP-Sr-CPC after 14 days immersion, but the combination effects of CGRP and Sr were only slightly increased, which may suggest that the enhanced effects of Sr and CGRP depend on the concentration of CGRP or rely on the stage of proliferation and osteogenic differentiation. We also noticed that the concentration of Sr on day 28 is about 54 mg/L (0.62 mmol/L), which is lower than the necessary concentration of Sr (1 mmol/L) released from strontium ranelate to induce ALP activity and formation of mineralized nodules in cultured BMSCs (46). This may be associated with the poor effects of Sr-CPC on bone mass growth in OVX rats compared with those of strontium ranelate (30).
To comprehensively understand the impact of CGRP-Sr-CPC and other cements on osteogenic differentiation of BMSCs, additional measurements including calcium deposition and matrix mineralization should be assayed. Meanwhile, the underlying mechanisms for how CGRP and Sr enhance proliferation and osteogenic differentiation should be addressed further in the future.
In addition to measuring the effects of immobilized Sr, immobilized CGRP or immobilized Sr and CGRP (CGRP-Sr-CPC) on proliferation and differentiation of BMSCs from OVX rats, we further assayed the roles of the combination of immobilized Sr (Sr-CPC) and free CGRP (CGRP/Sr-CPC). Interestingly, CGRP-Sr-CPC and CGRP/Sr-CPC had similar effects on promoting proliferation and osteogenic differentiation of BMSCs, which suggests that the combination of immobilized Sr with a locally released CGRP may also have enhancement effects. This indicates that adding free CGRP to SR-CPC could be an alternative to assist therapy of osteoporotic bone fractures.
In conclusion, in this study we created a modified CPC with Sr and CGRP incorporation and demonstrated the potential abilities of this novel cement to assist the formation of new bone. Considering that CGRP-Sr-CPC promotes proliferation and and osteogenic differentiation of BMSCs derived from osteoporotic conditions, it is attractive for us to further evaluate the effects of CGRP-Sr-CPC in promoting cell mineralization and formation of calcium nodules in vitro. Furthermore, the effects of CGRP-Sr-CPC on regulation of bone density, bone mass and bone growth in an in vivo model, especially in an osteoporotic animal model, will be examined in future studies.
Acknowledgement
We thank all other members of Dr. Bing Li’s laboratory for their technical support and helpful discussions. We also thank our colleagues for critical reading and edits.
Disclosures
Financial support: This study is supported by National Natural Science Foundation of China (No:81260273).
Conflict of interest: The authors declare that they have no conflicts of interest.
References
1.KanisJAMeltonLJ3rdChristiansenCJohnstonCCKhaltaevNThe diagnosis of osteoporosis.J Bone Miner Res1994911371141Google Scholar
2.KanisJADiagnosis of osteoporosis and assessment of fracture risk.Lancet2002359932119291936Google Scholar
3.PinoAMRosenCJRodríguezJPIn osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis.Biol Res2012453279287Google Scholar
4.LipsKSKauschkeVHartmannSet al.Cholinergic nerve fibers in bone defects of a rat osteoporosis model and their regulation by implantation of bone substitution materials.J Musculoskelet Neuronal Interact2014142173188Google Scholar
5.FengXMcDonaldJMDisorders of bone remodeling.Annu Rev Pathol201161121145Google Scholar
6.TogariAAraiMPharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption.J Pharmacol Sci20081064542546Google Scholar
7.IrieKHara-IrieFOzawaHYajimaTCalcitonin gene-related peptide (CGRP)-containing nerve fibers in bone tissue and their involvement in bone remodeling.Microsc Res Tech20025828590Google Scholar
8.ImaiSMatsusueYNeuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone.Microsc Res Tech20025826169Google Scholar
9.XuGJiangDThe role and mechanism of exogenous calcitonin gene-related peptide on mesenchymal stem cell proliferation and osteogenetic formation.Cell Biochem Biophys2014692369378Google Scholar
10.LiJWangYLiYSunJZhaoGThe effect of combined regulation of the expression of peroxisome proliferator-activated receptor-γ and calcitonin gene-related peptide on alcohol-induced adipogenic differentiation of bone marrow mesenchymal stem cells.Mol Cell Biochem20143921-23948Google Scholar
11.LiangWZhuoXTangZWeiXLiBCalcitonin gene-related peptide stimulates proliferation and osteogenic differentiation of osteoporotic rat-derived bone mesenchymal stem cells.Mol Cell Biochem20154021-2101110Google Scholar
12.WennerbergAAlbrektssonTStructural influence from calcium phosphate coatings and its possible effect on enhanced bone integration.Acta Odontol Scand2009676333340Google Scholar
13.JunkerRDimakisAThoneickMJansenJAEffects of implant surface coatings and composition on bone integration: a systematic review.Clin Oral Implants Res200920Suppl 4185206Google Scholar
14.DoblaréMGarcíaJMOn the modelling bone tissue fracture and healing of the bone tissue.Acta Cient Venez20035415875Google Scholar
15.WuJXuSQiuZet al.Comparison of human mesenchymal stem cells proliferation and differentiation on poly(methyl methacrylate) bone cements with and without mineralized collagen incorporation.J Biomater Appl2015Google Scholar
16.ChowLCNext generation calcium phosphate-based biomaterials.Dent Mater J2009281110Google Scholar
17.Van StadenADDicksLMCalcium orthophosphate-based bone cements (CPCs): applications, antibiotic release and alternatives to antibiotics.J Appl Biomater Funct Mater2012101211Google Scholar
18.HakDJThe use of osteoconductive bone graft substitutes in orthopaedic trauma.J Am Acad Orthop Surg2007159525536Google Scholar
19.QuYYangYLiJet al.Preliminary evaluation of a novel strong/osteoinductive calcium phosphate cement.J Biomater Appl2011263311325Google Scholar
20.IlliOEFeldmannCPStimulation of fracture healing by local application of humoral factors integrated in biodegradable implants.Eur J Pediatr Surg199884251255Google Scholar
21.YokotaSUchidaTKokuboSet al.Release of recombinant human bone morphogenetic protein 2 from a newly developed carrier.Int J Pharm20032511-25766Google Scholar
22.MinSXJinAMTongBHZhuLXTianJ:Three-dimensional porous poly-DL-lactide/basic fibroblast growth factor composites for bone defect repair: an experimental study.Di Yi Jun Yi Da Xue Xue Bao2003234318322Google Scholar
23.ArmDMTencerAFBainSDCelinoDEffect of controlled release of platelet-derived growth factor from a porous hydroxyapatite implant on bone ingrowth.Biomaterials1996177703709Google Scholar
24.LaffarguePFialdesPFrayssinetPRtaimateMHildebrandHFMarchandiseXAdsorption and release of insulin-like growth factor-I on porous tricalcium phosphate implant.J Biomed Mater Res2000493415421Google Scholar
25.BaronRTsouderosYIn vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation.Eur J Pharmacol200245011117Google Scholar
26.TakahashiNSasakiTTsouderosYSudaTS 12911-2 inhibits osteoclastic bone resorption in vitro.J Bone Miner Res200318610821087Google Scholar
27.YangFTuJYangDLiGCaiLWangLOsteogenic differentiation of mesenchymal stem cells could be enhanced by strontium.Proceedings of the annual international conference of the IEEE Engineering in Medicine and Biology Society,2010pp. 823826https://ieeexplore.ieee.org/xpl/articleDetails.jsp?arnumber=5626774.Google Scholar
28.ParkJWKimYJJangJHSongHPositive modulation of osteogenesis- and osteoclastogenesis-related gene expression with strontium-containing microstructured Ti implants in rabbit cancellous bone.J Biomed Mater Res A20131011298306Google Scholar
29.KuangGMYauWPLamWMet al.An effective approach by a chelate reaction in optimizing the setting process of strontium-incorporated calcium phosphate bone cement.J Biomed Mater Res B Appl Biomater20121003778787Google Scholar
30.BaierMStaudtPKleinRet al.Strontium enhances osseointegration of calcium phosphate cement: a histomorphometric pilot study in ovariectomized rats.J Orthop Surg20138116Google Scholar
31.MiyamotoYIshikawaKTakechiMet al.Non-decay type fast-setting calcium phosphate cement: setting behaviour in calf serum and its tissue response.Biomaterials1996171414291435Google Scholar
32.BohnerMGbureckUBarraletJETechnological issues for the development of more efficient calcium phosphate bone cements: a critical assessment.Biomaterials2005263364236429Google Scholar
33.MüllerLMüllerFAPreparation of SBF with different HCO3- content and its influence on the composition of biomimetic apatites.Acta Biomater200622181189Google Scholar
34.ZhangDWangXLiuMZhangLDengMLiuHQuantification of strontium in human serum by ICP-MS using alternate analyte-free matrix and its application to a pilot bioequivalence study of two strontium ranelate oral formulations in healthy Chinese subjects.J Trace Elem Med Biol2015296974Google Scholar
35.XieZChenYLiZet al.Smad6 promotes neuronal differentiation in the intermediate zone of the dorsal neural tube by inhibition of the Wnt/beta-catenin pathway.Proc Natl Acad Sci USA2011108291211912124Google Scholar
36.ChattopadhyayNQuinnSJKiforOYeCBrownEMThe calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.Biochem Pharmacol2007743438447Google Scholar
37.MeunierPJRouxCSeemanEet al.The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.N Engl J Med20043505459468Google Scholar
38.ReginsterJYSeemanEDe VernejoulMCet al.Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.J Clin Endocrinol Metab200590528162822Google Scholar
39.van RossumDHanischUKQuirionRNeuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors.Neurosci Biobehav Rev1997215649678Google Scholar
40.RosenfeldMGMermodJJAmaraSGet al.Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing.Nature19833045922129135Google Scholar
42.LernerUHDeletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone.J Musculoskelet Neuronal Interact2006618795Google Scholar
43.MikamiNMiyagiYSuedaKet al.Calcitonin gene-related peptide and cyclic adenosine 5’-monophosphate/protein kinase A pathway promote IL-9 production in Th9 differentiation process.J Immunol2013190840464055Google Scholar
44.StevensonJCMacdonaldDWWarrenRCBookerMWWhiteheadMIIncreased concentration of circulating calcitonin gene related peptide during normal human pregnancy.Br Med J (Clin Res Ed)1986293655813291330Google Scholar
45.WimalawansaSJCalcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials.Endocr Rev1996175533585Google Scholar
46.LvHHuangXJinSGuoRWuW[Strontium ranelate promotes osteogenic differentiation of rat bone mesenchymal stem cells through bone morphogenetic protein-2/Smad signaling pathway] [article in Chinese].Nan Fang Yi Ke Da Xue Xue Bao2013333376381Google Scholar
Fourth Affiliated Hospital, Guangxi Medical University, Guangxi - PR China
Guangxi Medical University, Guangxi - PR China
Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen - PR China
W. Liang and L. Li contributed equally to this study.
Article usage statistics
The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.
This article has supplementary materials available to download.